Conditions: Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8
Interventions: Drug: Alectinib; Drug: Alpelisib; Drug: Anastrozole; Biological: Atezolizumab; Biological: Bevacizumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Capecitabine; Drug: Carboplatin; Drug: Cobimetinib; Drug: Entrectinib; Drug: Eribulin; Drug: Fulvestrant; Biological: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab; Drug: Irinotecan; Drug: Letrozole; Drug: Nab-paclitaxel; Drug: Niraparib; Drug: Olaparib; Drug: Paclitaxel; Drug: Palbociclib; Biological: Pertuzumab; Other: Quality-of-Life Assessment; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Vemurafenib; Drug: Vinorelbine; Drug: Vismodegib
Sponsors: OHSU Knight Cancer Institute; Genentech, Inc.; Oregon Health and Science University
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
